Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2013

Open Access 01-12-2013 | Original investigation

Arg972 Insulin receptor substrate-1 is associated with decreased serum angiotensin-converting enzyme 2 levels in acute myocardial infarction patients: in vivo and in vitro evidence

Authors: Wei Liu, Xinmin Zhou, Fenglei Yu, Jianguo Hu, Wen Hu

Published in: Cardiovascular Diabetology | Issue 1/2013

Login to get access

Abstract

Background

Activation of the renin-angiotensin system (RAS) plays a critical role in the pathophysiology of myocardial infarction (MI) and the development of heart failure. Both angiotensin-converting enzyme 2 (ACE2) and insulin/insulin receptor substrate-1 (IRS-1) show cardioprotective effects after acute MI. The Arg972 IRS-1 polymorphism is associated with diminished activity of insulin. In the present study, we explored the association among Arg972 IRS-1, acute MI, and serum levels of ACE2.

Methods

A total of 711 subjects, including 351 subjects with first-time acute MI and 360 subjects without a history of MI were genotyped for Arg972 IRS-1 polymorphism. Serum levels of ACE2 and MI severity scores were determined. Primary human cardiomyocytes with overexpression of wild type IRS-1 or Arg972 IRS-1 or knockdown of endogenous IRS-1 were exposed to normoxia and hypoxia, and the expression levels of ACE2 were determined.

Results

The serum ACE2 level was significantly increased in acute MI patients compared with that of non-MI controls. Compared with wild type IRS-1 carriers, Arg972 IRS-1 carriers exhibited decreased serum ACE2 levels and increased MI severity scores after MI. Our in vitro data demonstrate that impairment of insulin/IRS-1/PI3K signaling by overexpression of Arg972-IRS-1, knockdown of endogenous IRS-1, or PI3K inhibitor can abolish hypoxia-induced IRS-1-associated PI3K activity and ACE2 expression in human cardiomyocytes, which suggests a causal relationship between Arg972-IRS-1 and decreased serum ACE2 levels in acute MI patients. Our in vitro data also indicate that insulin/IRS-1/PI3K signaling is required for ACE2 expression in cardiomyocytes, and that hypoxia can enhance the induction effect of insulin/IRS-1/PI3K signaling on ACE2 expression in cardiomyocytes.

Conclusions

This study provides the first evidence of crosstalk between insulin/IRS-1/PI3K signaling and RAS after acute MI, thereby adding fresh insights into the pathophysiology and treatment of acute MI.
Appendix
Available only for authorised users
Literature
1.
go back to reference Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM: Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. Clin Sci (Lond). 2012, 123: 649-658. 10.1042/CS20120162.CrossRef Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM: Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. Clin Sci (Lond). 2012, 123: 649-658. 10.1042/CS20120162.CrossRef
2.
go back to reference Mazzolai L, Pedrazzini T, Nicoud F, Gabbiani G, Brunner HR, Nussberger J: Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensives mice. Hypertension. 2000, 35: 985-991. 10.1161/01.HYP.35.4.985.CrossRefPubMed Mazzolai L, Pedrazzini T, Nicoud F, Gabbiani G, Brunner HR, Nussberger J: Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensives mice. Hypertension. 2000, 35: 985-991. 10.1161/01.HYP.35.4.985.CrossRefPubMed
3.
go back to reference Raizada MK, Ferreira AJ: ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol. 2007, 50: 112-119. 10.1097/FJC.0b013e3180986219.CrossRefPubMed Raizada MK, Ferreira AJ: ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol. 2007, 50: 112-119. 10.1097/FJC.0b013e3180986219.CrossRefPubMed
4.
go back to reference Burrell LM, Risvanis J, Kubota E, Dean RG, MacDonald PS, Lu S, Tikellis C, Grant SL, Lew RA, Smith AI, Cooper ME, Johnston CI: Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J. 2005, 114: 1-7. Burrell LM, Risvanis J, Kubota E, Dean RG, MacDonald PS, Lu S, Tikellis C, Grant SL, Lew RA, Smith AI, Cooper ME, Johnston CI: Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J. 2005, 114: 1-7.
5.
go back to reference Hamming I, Cooper ME, Haagmans BL, Hooper NM, Korstanje R, Osterhaus AD, Timens W, Turner AJ, Navis G, van Goor H: The emerging role of ACE2 in physiology and disease. J Pathol. 2007, 212: 1-11. 10.1002/path.2162.CrossRefPubMed Hamming I, Cooper ME, Haagmans BL, Hooper NM, Korstanje R, Osterhaus AD, Timens W, Turner AJ, Navis G, van Goor H: The emerging role of ACE2 in physiology and disease. J Pathol. 2007, 212: 1-11. 10.1002/path.2162.CrossRefPubMed
6.
go back to reference Der Sarkissian S, Grobe JL, Yuan L, Narielwala DR, Walter GA, Katovich MJ, Raizada MK: Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension. 2008, 51: 712-718. 10.1161/HYPERTENSIONAHA.107.100693.CrossRefPubMed Der Sarkissian S, Grobe JL, Yuan L, Narielwala DR, Walter GA, Katovich MJ, Raizada MK: Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension. 2008, 51: 712-718. 10.1161/HYPERTENSIONAHA.107.100693.CrossRefPubMed
7.
go back to reference Zhao Y, Yin HQ, Yu QT, Qiao Y, Dai HY, Zhang MX, Zhang L, Liu YF, Wang LC, Liu de S, Deng BP, Zhang YH, Pan CM, Song HD, Qu X, Jiang H, Liu CX, Lu XT, Liu B, Gao F, Dong B: ACE2 overexpression ameliorates left ventricular remodeling and function in rats with myocardial infarction. Hum Gene Ther. 2010, 21: 1545-1554. 10.1089/hum.2009.160.CrossRefPubMed Zhao Y, Yin HQ, Yu QT, Qiao Y, Dai HY, Zhang MX, Zhang L, Liu YF, Wang LC, Liu de S, Deng BP, Zhang YH, Pan CM, Song HD, Qu X, Jiang H, Liu CX, Lu XT, Liu B, Gao F, Dong B: ACE2 overexpression ameliorates left ventricular remodeling and function in rats with myocardial infarction. Hum Gene Ther. 2010, 21: 1545-1554. 10.1089/hum.2009.160.CrossRefPubMed
8.
go back to reference Perez JTO, Riera M, Genover XB, De Caralt TM, Perea RJ: Serum ACE2 activity correlates with infarct size and left ventricular dysfunction during acute myocardial infarction. J Cardiovas Magn Res. 2011, 13 (Suppl 1): 142-10.1186/1532-429X-13-S1-P142.CrossRef Perez JTO, Riera M, Genover XB, De Caralt TM, Perea RJ: Serum ACE2 activity correlates with infarct size and left ventricular dysfunction during acute myocardial infarction. J Cardiovas Magn Res. 2011, 13 (Suppl 1): 142-10.1186/1532-429X-13-S1-P142.CrossRef
9.
go back to reference Nagoshi T, Matsui T, Aoyama T, Leri A, Anversa P, Li L, Ogawa W, del Monte F, Gwathmey JK, Grazette L, Hemmings BA, Kass DA, Champion HC, Rosenzweig A: PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J Clin Invest. 2005, 115: 2128-2138. 10.1172/JCI23073.PubMedCentralCrossRefPubMed Nagoshi T, Matsui T, Aoyama T, Leri A, Anversa P, Li L, Ogawa W, del Monte F, Gwathmey JK, Grazette L, Hemmings BA, Kass DA, Champion HC, Rosenzweig A: PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J Clin Invest. 2005, 115: 2128-2138. 10.1172/JCI23073.PubMedCentralCrossRefPubMed
10.
go back to reference King KL, Opie LH: Glucose and glycogen utilization in myocardial ischemia-changes in metabolism and consequences for the myocyte. Mol Cell Biochem. 1998, 180: 3-26. 10.1023/A:1006870419309.CrossRefPubMed King KL, Opie LH: Glucose and glycogen utilization in myocardial ischemia-changes in metabolism and consequences for the myocyte. Mol Cell Biochem. 1998, 180: 3-26. 10.1023/A:1006870419309.CrossRefPubMed
11.
go back to reference Apstein CS, Opie LH: Glucose-insulin-potassium (GIK) for acute myocardial infarction: a negative study with a positive value. Cardiovasc Drugs Ther. 1999, 13: 185-189. 10.1023/A:1007757407246.CrossRefPubMed Apstein CS, Opie LH: Glucose-insulin-potassium (GIK) for acute myocardial infarction: a negative study with a positive value. Cardiovasc Drugs Ther. 1999, 13: 185-189. 10.1023/A:1007757407246.CrossRefPubMed
12.
go back to reference Maarman G, Marais E, Lochner A, du Toit EF: Effect of chronic CPT-1 inhibition on myocardial ischemia-reperfusion injury (I/R) in a model of diet-induced obesity. Cardiovasc Drugs Ther. 2012, 26: 205-216. 10.1007/s10557-012-6377-1.CrossRefPubMed Maarman G, Marais E, Lochner A, du Toit EF: Effect of chronic CPT-1 inhibition on myocardial ischemia-reperfusion injury (I/R) in a model of diet-induced obesity. Cardiovasc Drugs Ther. 2012, 26: 205-216. 10.1007/s10557-012-6377-1.CrossRefPubMed
13.
go back to reference Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, Quon MJ: Roles for insulin receptor, PI3-kinase, and Akt in insulin signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation. 2000, 101: 1539-1545. 10.1161/01.CIR.101.13.1539.CrossRefPubMed Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, Quon MJ: Roles for insulin receptor, PI3-kinase, and Akt in insulin signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation. 2000, 101: 1539-1545. 10.1161/01.CIR.101.13.1539.CrossRefPubMed
14.
go back to reference Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T, Feener EP, Herbert TP, Rhodes CJ, King GL: Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation. 2000, 101: 676-681. 10.1161/01.CIR.101.6.676.CrossRefPubMed Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T, Feener EP, Herbert TP, Rhodes CJ, King GL: Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation. 2000, 101: 676-681. 10.1161/01.CIR.101.6.676.CrossRefPubMed
15.
go back to reference Fallucca F, Dalfrà MG, Sciullo E, Masin M, Buongiorno AM, Napoli A, Fedele D, Lapolla A: Polymorphisms of insulin receptor substrate 1 and beta3-adrenergic receptor genes in gestational diabetes and normal pregnancy. Metabolism. 2006, 55: 1451-1456. 10.1016/j.metabol.2006.06.004.CrossRefPubMed Fallucca F, Dalfrà MG, Sciullo E, Masin M, Buongiorno AM, Napoli A, Fedele D, Lapolla A: Polymorphisms of insulin receptor substrate 1 and beta3-adrenergic receptor genes in gestational diabetes and normal pregnancy. Metabolism. 2006, 55: 1451-1456. 10.1016/j.metabol.2006.06.004.CrossRefPubMed
16.
go back to reference Huang C, Lin Z, Zhou Y, Fang M, Sun S, Jiang W, Dong H, Lv B, Lan H, Chen M, Yang T, Zeng H, Chen J: Arg(972) insulin receptor substrate-1 is associated with elevated plasma endothelin-1 level in hypertensives. J Hypertens. 2012, 30: 1751-1757. 10.1097/HJH.0b013e3283561400.CrossRefPubMed Huang C, Lin Z, Zhou Y, Fang M, Sun S, Jiang W, Dong H, Lv B, Lan H, Chen M, Yang T, Zeng H, Chen J: Arg(972) insulin receptor substrate-1 is associated with elevated plasma endothelin-1 level in hypertensives. J Hypertens. 2012, 30: 1751-1757. 10.1097/HJH.0b013e3283561400.CrossRefPubMed
17.
go back to reference Federici M, Petrone A, Porzio O, Bizzarri C, Lauro D, D'Alfonso R, Patera I, Cappa M, Nisticò L, Baroni M, Sesti G, di Mario U, Lauro R, Buzzetti R: The Gly972→Arg IRS-1 variant is associated with type 1 diabetes in continental Italy. Diabetes. 2003, 52: 887-890. 10.2337/diabetes.52.3.887.CrossRefPubMed Federici M, Petrone A, Porzio O, Bizzarri C, Lauro D, D'Alfonso R, Patera I, Cappa M, Nisticò L, Baroni M, Sesti G, di Mario U, Lauro R, Buzzetti R: The Gly972→Arg IRS-1 variant is associated with type 1 diabetes in continental Italy. Diabetes. 2003, 52: 887-890. 10.2337/diabetes.52.3.887.CrossRefPubMed
18.
go back to reference Yang W, Huang W, Su S, Li B, Zhao W, Chen S, Gu D: Association study of ACE2 (angiotensin I-converting enzyme 2) gene polymorphisms with coronary heart disease and myocardial infarction in a Chinese Han population. Clin Sci (Lond). 2006, 111: 333-340. 10.1042/CS20060020.CrossRef Yang W, Huang W, Su S, Li B, Zhao W, Chen S, Gu D: Association study of ACE2 (angiotensin I-converting enzyme 2) gene polymorphisms with coronary heart disease and myocardial infarction in a Chinese Han population. Clin Sci (Lond). 2006, 111: 333-340. 10.1042/CS20060020.CrossRef
19.
go back to reference Myerson M, Coady S, Taylor H, Rosamond WD, Goff DC: Declining severity of myocardial infarction from 1987 to 2002: the atherosclerosis risk in communities (ARIC) study. Circulation. 2009, 119: 503-514. 10.1161/CIRCULATIONAHA.107.693879.CrossRefPubMed Myerson M, Coady S, Taylor H, Rosamond WD, Goff DC: Declining severity of myocardial infarction from 1987 to 2002: the atherosclerosis risk in communities (ARIC) study. Circulation. 2009, 119: 503-514. 10.1161/CIRCULATIONAHA.107.693879.CrossRefPubMed
20.
go back to reference Porzio O, Federici M, Hribal ML, Lauro D, Accili D, Lauro R, Borboni P, Sesti G: The Gly972–>Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic beta cells. J Clin Invest. 1999, 104: 357-364. 10.1172/JCI5870.PubMedCentralCrossRefPubMed Porzio O, Federici M, Hribal ML, Lauro D, Accili D, Lauro R, Borboni P, Sesti G: The Gly972–>Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic beta cells. J Clin Invest. 1999, 104: 357-364. 10.1172/JCI5870.PubMedCentralCrossRefPubMed
21.
go back to reference Holmquist L, Jo¨gi A, Pa˚hlman S: Phenotypic persistence after reoxygenation of hypoxic neuroblastoma cells. Int J Cancer. 2005, 116: 218-225. 10.1002/ijc.21024.CrossRefPubMed Holmquist L, Jo¨gi A, Pa˚hlman S: Phenotypic persistence after reoxygenation of hypoxic neuroblastoma cells. Int J Cancer. 2005, 116: 218-225. 10.1002/ijc.21024.CrossRefPubMed
22.
go back to reference Matsui T, Li L, del Monte F, Fukui Y, Franke TF, Hajjar RJ, Rosenzweig A: Adenoviral gene transfer of activated PI 3-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation. 1999, 100: 2373-2379. 10.1161/01.CIR.100.23.2373.CrossRefPubMed Matsui T, Li L, del Monte F, Fukui Y, Franke TF, Hajjar RJ, Rosenzweig A: Adenoviral gene transfer of activated PI 3-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation. 1999, 100: 2373-2379. 10.1161/01.CIR.100.23.2373.CrossRefPubMed
23.
go back to reference Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, Hooper NM, Turner AJ: Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem. 2005, 280: 30113-30119. 10.1074/jbc.M505111200.CrossRefPubMed Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, Hooper NM, Turner AJ: Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem. 2005, 280: 30113-30119. 10.1074/jbc.M505111200.CrossRefPubMed
24.
go back to reference Rzymski T, Petry A, Kračun D, Rieß F, Pike L, Harris AL, Görlach A: The unfolded protein response controls induction and activation of ADAM17/TACE by severe hypoxia and ER stress. Oncogene. 2012, 31: 3621-3634. 10.1038/onc.2011.522.CrossRefPubMed Rzymski T, Petry A, Kračun D, Rieß F, Pike L, Harris AL, Görlach A: The unfolded protein response controls induction and activation of ADAM17/TACE by severe hypoxia and ER stress. Oncogene. 2012, 31: 3621-3634. 10.1038/onc.2011.522.CrossRefPubMed
25.
go back to reference Handley MG, Medina RA, Nagel E, Blower PJ, Southworth R: PET imaging of cardiac hypoxia: opportunities and challenges. J Mol Cell Cardiol. 2011, 51: 640-650. 10.1016/j.yjmcc.2011.07.005.PubMedCentralCrossRefPubMed Handley MG, Medina RA, Nagel E, Blower PJ, Southworth R: PET imaging of cardiac hypoxia: opportunities and challenges. J Mol Cell Cardiol. 2011, 51: 640-650. 10.1016/j.yjmcc.2011.07.005.PubMedCentralCrossRefPubMed
26.
go back to reference Povel CM, Boer JM, Onland-Moret NC, Dollé ME, Feskens EJ, van der Schouw YT: Single nucleotide polymorphisms (SNPs) involved in insulin resistance, weight regulation, lipid metabolism and inflammation in relation to metabolic syndrome: an epidemiological study. Cardiovasc Diabetol. 2012, 11: 133-10.1186/1475-2840-11-133.PubMedCentralCrossRefPubMed Povel CM, Boer JM, Onland-Moret NC, Dollé ME, Feskens EJ, van der Schouw YT: Single nucleotide polymorphisms (SNPs) involved in insulin resistance, weight regulation, lipid metabolism and inflammation in relation to metabolic syndrome: an epidemiological study. Cardiovasc Diabetol. 2012, 11: 133-10.1186/1475-2840-11-133.PubMedCentralCrossRefPubMed
27.
go back to reference Underwood PC, Adler GK: The renin angiotensin aldosterone system and insulin resistance in humans. Curr Hypertens Rep. 2013, 15: 59-70. 10.1007/s11906-012-0323-2.PubMedCentralCrossRefPubMed Underwood PC, Adler GK: The renin angiotensin aldosterone system and insulin resistance in humans. Curr Hypertens Rep. 2013, 15: 59-70. 10.1007/s11906-012-0323-2.PubMedCentralCrossRefPubMed
Metadata
Title
Arg972 Insulin receptor substrate-1 is associated with decreased serum angiotensin-converting enzyme 2 levels in acute myocardial infarction patients: in vivo and in vitro evidence
Authors
Wei Liu
Xinmin Zhou
Fenglei Yu
Jianguo Hu
Wen Hu
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2013
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-12-151

Other articles of this Issue 1/2013

Cardiovascular Diabetology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.